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Abstract
Background: Studies over the past decade and half have identified cancer stem cells (CSCs) to be responsible for
tumorigenesis, invasion, sustenance of metastatic disease, radio- and chemo-resistance and tumor relapse. Recent
reports have described the plasticity of breast CSCs (BCSCs) to shift between the epithelial and mesenchymal
phenotypes via Epithelial-Mesenchymal Transition (EMT) and Mesenchymal-Epithelial Transition (MET) states as the
reason for their invasive capabilities. Additionally, BRCA1 has been found to be a mammary stem cell fate determinant.
However, it is not clear what would be the best marker that can be used for identifying CSCs in BRCA1 mutated cancers.
Also, anticancer agents that can reduce CSC population in a BRCA1 defective condition have not been addressed so far.
Methods: Putative BCSCs were identified based on Hoechst exclusion, CD44+/24–/low expression and Aldehyde
Dehydrogenase 1 (ALDH1) positivity using flow cytometry. The ‘stemness’ of the isolated ALDH1+ cells were analysed
by immunofluorescence, western blotting for stem cell and EMT markers as well as in vitro mammosphere assays.
Induction of Reactive Oxygen Species (ROS) by Plumbagin (PB) in BCSCs was assayed by Dichloro-dihydro-fluorescein
diacetate (DCF-DA) staining. Ovarian cancer xenografts treated with PB were subjected to immunohistochemical
analysis to study the ability of PB to target CSCs.
Results: We have confirmed that ALDH1 positivity is the best marker for the identification of BCSCs in BRCA1-defective
breast cancer cell lines when compared to the CD marker profile and Side Population (SP) analysis. BRCA1 status was
observed to be a determinant of the abundance of epithelial-like (ALDH1+) or mesenchymal-like (CD44+/24–/low) BCSCs,
and the reconstitution of a full length, wild type BRCA1 in HCC1937 breast cancer cells possessing a mutated BRCA1,
transforms them from ‘stem-like’ to more ‘mesenchymal’. For the first time we have shown that Plumbagin (PB), a
naturally occurring naphthoquinone which is predominantly a ROS inducer, could reduce BCSCs specifically in
BRCA1-defective, basal-like cancer cells.
Conclusions: The best marker for identifying BCSCs in BRCA1 defective condition could be ALDH1 and that BRCA1
mutated BCSCs would be mostly ‘stem like’ than ‘mesenchymal’. Also ROS inducers like PB could reduce BCSCs in
BRCA1 defective cancers.
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Background
In 1858, Rudolf Virchow proposed the embryonal rest
theory of cancer [1]. This was the first ever reference to the
possibility that a stem cell that stayed dormant during
embryonic development and for years later could eventually
become a cancer initiator. Julius Conheim corroborated this
in striated muscle sarcoma of the kidneys [2]. After ‘resting’
for almost a century and half since its first mention, the
embryonal rest theory was revived as the CSC hypothesis
and then began the hunt for biomarkers to identify CSCs.
Once the existence of a therapy resistant population within
a tumor that could possibly be the origin of tumorigenesis
as well the reason for relapse was scientifically shown in
leukemia [3], the Cancer Stem Cell hypothesis has been
rapidly gaining support from various quarters. The exist-
ence of CSCs in breast cancer was first brought to light
when it was found that the CD44+CD24−/lowLin− cells from
breast cancer patients were able to generate tumors more
efficiently than CD44+CD24+Lin− cells when implanted
into the mammary fat pads of NOD/SCID mice [4]. Also,
these cells exhibited the typical stem-like characteristics of
self-renewal (surviving serial passage) and differentiation
(reproducing the tumor heterogeneity as in the primary
tumor). Subsequently, a number of markers, including
ALDH1 were discovered for BCSCs with special reference
to the different molecular sub-types with many of the
markers being common to normal mammary stem cells as
well as BCSCs [5–14]. However, most biomarkers till date
have not stood the test of time. This, in addition to the
difficulties of accurate xenograft studies have prevented the
CSC hypothesis from evolving into a theory.
The best possible method would be to restrict a study to
a single subtype of cancer and try to find markers specific
to CSCs in the said cancer type as the dearth of currently
known distinct, distinguishing features for identification of
CSCs means that there is a long way to go in the identifica-
tion (if at all) of specific CSC marker/s for every cancer
type.
BRCA1-defective tumors represent a class of early onset,
high grade, poor prognosis, often triple negative breast
cancers (TNBCs) with no specific or selective treatment
regimen [15]. BRCA1 is a transcriptional regulator and
plays a cardinal role in Homologous Recombination Repair
of damaged DNA [16–18]. Later, it was found to be im-
portant in embryonic development and was subsequently
reported to be a determinant of the mammary stem cell
fate [19, 20]. However, the characteristics of BCSCs from
BRCA1-defective cancers are largely unexplored. Earlier
studies from our group have revealed the ability of PB (5-
hydroxy-2-methyl-1, 4-naphthoquinone) to selectively tar-
get BRCA1-defective ovarian cancer cells [21–24] as well
as BRCA1-knockout breast cancer xenografts (unpublished
data). Even though PB acts via multiple pathways to induce
cytotoxicity in cancer cells, the major mode of action is the
generation of ROS and subsequent DNA damage which
could be especially deleterious to BRCA1-defective cancer
cells that lack the homologous recombination repair ma-
chinery [21–28]. Therefore, in this study we analyzed the
ability of PB to target BCSCs from BRCA1-defective
cancers.
Here we report that ALDH1 positivity could be one of
the best markers for the identification of BCSCs from
basal-like, BRCA1-defective breast cancer cell lines based
on the isolation of putative CSCs followed by their in vitro
mammosphere culture. We have also shown for the first
time that PB can target CSCs wherein the BCSCs derived
from the cells possessing a reconstituted BRCA1, show an
enrichment of ALDH1+ cells upon PB treatment. The
BRCA1-defective HCC1937 shows a robust down regula-
tion of ALDH1 positivity after treatment with sub-cytotoxic
doses of PB. On the other hand, the standard drug carbo-
platin (CP) increased ALDH1+ cells in both the cell lines,




Human breast epithelial adenocarcinoma cell lines (MCF7,
MDA-MB-231, MDA-MB-436), and a human ovarian
adenocarcinoma cell line (OVCAR-5) were purchased
from American Type Culture Collection (ATCC, Manas-
sas, VA, USA). Human breast ductal carcinoma cell line;
HCC1937 and HCC1937 reconstituted with wild type
BRCA1 (HCC1937/wt BRCA1) were kind gifts from Dr.
Grant Mc Arthur, Peter MacCallum Cancer Centre, VIC,
Australia. All the cell lines were maintained in culture
medium containing 10 % Fetal Bovine Serum (FBS) (PAN-
Biotech GmBH, Aidenbach, Germany), 0.1 g/L Strepto-
mycin (Sigma Aldrich, St. Louis, MO, USA) and 100U/L
Penicillin in a humidified incubator at 37 °C in 5 % (v/v)
CO2. MCF7, MDA-MB-231 and OVCAR-5 were main-
tained in Dulbecco’s Modified Eagles’ Medium (Gibco,
Carlsbad, CA, USA), MDA-MB-436 in RPMI 1640 (PAN-
Biotech GmBH, Aidenbach, Germany) and HCC1937 and
HCC1937/wt BRCA1 in RPMI 1640 with insulin (5 μg/
ml). Passage numbers post thawing of the cell lines were
noted and experiments were carried out within a maximal
passage number (<30).
Cell viability assay
MTT assay to assess the effects of 48 h treatment with
PB and CP on HCC1937 and HCC1937/wt BRCA1 was
performed as described elsewhere [23]. 3–(4,5-Dimethyl
thiazol-2-yl) 2,5-diphenyl tetrazolium bromide (MTT) was
purchased from USB, Cleveland, OH, USA, PB and CP
were from Sigma Aldrich, St. Louis, MO, USA. CP solu-
tions were prepared in phosphate buffered saline (PBS)
immediately before the experiment. PB was dissolved in
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Dimethyl Sulfoxide (DMSO) and the vehicle control
(DMSO) did not show any effect on cell viability. All re-
sults are expressed as the percentage cell viability over
control ± S.D. of quadruplicate determinations from three
independent experiments.
Side population analysis
Cells were stained with 5 μg/ml of Hoechst 33,342 (Sigma
Aldrich, St. Louis, MO, USA) for 90 min in a 37 °C water
bath. Cells stained with 5 μg/ml Hoechst in the presence of
50 μM Verapamil Hydrochloride (calcium channel blocker
that prevents Hoechst efflux from cells) (Sigma Aldrich, St.
Louis, MO, USA) was used as negative control. The cells
were then stained with propidium iodide (PI) (2 μg/106
cells) for dead cell exclusion and sorted using BD FACSAr-
iaII flow cytometer (Becton Dickinson, Franklin Lakes, NJ,
USA). Hoechst 33,342 stained cells were analyzed using
350 nm excitation with blue (635 nm) and red (488 nm)
emission. BD FACSDiva Software was used for analysis.
Surface marker profiling
Cells were stained with Mouse anti-human CD44-APC
(C26) and CD24-FITC (ML5) antibodies (BD Biosciences
(San Jose, CA., USA)) for 30 min on ice. Cells stained with
CD44-APC and CD24-FITC separately (single color) were
taken as the controls. The 633 nm and 488 nm lasers were
used for excitation and 530/30 nm BP and 660/20 BP
detectors were used for CD24-FITC and CD44-APC
respectively. The CD44+/24–/low (putative stem cell) popu-
lation was identified and analyzed using flow cytometry as
mentioned above.
ALDEFLUOR assay
The ALDEFLUOR assay (The ALDEFLUOR Assay kit,
Stem Cell Technologies (Durham, NC, USA)) was used
to identify and isolate the ALDH+ cells from the various
cell lines. Briefly, cells in growing conditions or treated with
PB or CP for 48 h were suspended in ALDEFLUOR assay
buffer containing ALDH substrate (BODIPY-aminoacetal-
dehyde or BAAA, 1 μmol/l per 1 × 106 cells) and incubated
for 40 min at 37 °C in a water bath to assess the ALDH en-
zymatic activity. As negative control, an aliquot was treated
with 50 mmol/l diethylaminobenzaldehyde (DEAB), a spe-
cific ALDH inhibitor for each sample of cells. The ALDH1
positive (ALDH1+) and ALDH1 negative (ALDH1-) popu-
lations were sorted out by flow cytometry using the 488 nm
laser and the 530/30 nm BP detector as mentioned above.
In vitro propagation of BCSCs: mammosphere culture
Cells were seeded for primary mammosphere formation at
2000 cells/ml in ultralow attachment plates (Corning Inc.,
Corning, NY, USA) in MEBM (Mammary Epithelial Basal
Medium Bullet kit from Lonza (Basel, Switzerland)) con-
taining insulin (5 μg/ml) hydrocortisone (1 μg/ml), EGF
(10 ng/ml), bFGF (20 ng/ml) (BD Biosciences, San Jose,
CA), 2 % B27 serum free supplement (Life Technologies,
Carlsbad, CA, USA) and heparin (4 μg/ml) (Sigma Aldrich,
St. Louis, MO, USA). Medium was supplemented every
4 days. Mammospheres (>50 μm) were counted and photo-
graphed on day 7. The cells were treated with sub-cytotoxic
concentrations of PB (single dose) and cultured for 7 days
to study the sphere forming efficiency and ABCG2 expres-
sion. During the treatment, growth medium without PB
was supplemnted every 4 days.
3 D culture of spheroids
In order to recapitulate the mammosphere data in a system
that involves the extracellular matrix components as would
be seen in vivo, cells were seeded at 10,000 cells/ml in
RPMI with insulin (5 μg/ml /ml), hydrocortisone (1 μg/
ml), EGF (10 ng/ml) and 5 % Growth Factor Reduced
Matrigel (GFRM) to 8-well chamber slides (BD Falcon, San
Jose, CA, USA) pre-coated with 50 μl GFRM (BD Biosci-
ences, San Jose, CA, USA). 0.5 μM PB was added to the
cells. Cells were viewed on Day 5, Day 7, Day 10 and Day
15 using the Olympus IX71 microscope and photographed.
Immunofluorescence analysis
Day 7 mammospheres were washed with Phosphate Buff-
ered Saline (PBS) and fixed in 4 % paraformaldehyde.
Following permeabilization with 0.25 % Triton × 100, and
blocking with 1 % Bovine Serum Albumin (BSA), spheres
were incubated overnight at 4 °C in the primary antibody.
After PBS wash and incubation with fluorochrome tagged
secondary antibody for 2 h, spheres were mounted in
Prolong Gold Antifade with DAPI (Life Technologies,
Carlsbad, CA, USA) and viewed using the Olympus IX71
microscope. Immunofluorescence analysis was performed
with Rabbit anti-human Snail + Slug, rabbit anti-human β
catenin (E247), rabbit anti-human α-SMA (Smooth Muscle
Actin), and goat anti-human Oct 4 purchased from Abcam
(Cambridge, MA, USA), goat anti-human Vimentin
(C20), rabbit anti-human BRCA1, mouse anti-human
ABCG2 (6D17) from Santa Cruz Biotechnology (Santa
Cruz, CA, USA).
DCF-DA staining
ROS production in mammospheres was assessed from the
levels of bright green colored 2′,7′-dichlorofluorescein
(DCF), produced by the oxidation of DCF-DA (2′,7′-
Dichlorodihydrofluorescein diacetate) dye by ROS induced
in mammospheres after a 10 min treatment with 1 μM PB
followed by exposure to 500 nM DCF-DA (Sigma Aldrich,
St. Louis, MO, USA) (stock dissolved in Dimethyl formam-
ide and further diluted in PBS) for 20 min in dark at 37 °C.
The green fluorescence was detected by the Leica DMI
6000B microscope at 495/529 nm.
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Comet assay
A single gel electrophoresis method for comet assay with
modifications as described by Olive et al., 2006 was done.
Briefly, cells treated with PB for 4 h were lysed using
neutral lysis buffer overnight at 37 °C and seeded on to low
melting agarose gel in a frosted slide. Then electrophoresis
was done in Tris Borate EDTA buffer for 30 min at 50 V.
The slides were then stained with propidium iodide and
observed under an Olympus 1X71 fluorescent microscope
for comets. The comets formed were scored using Casplab
software.
Western blotting
Cell lysates were analyzed for expression of ABCG2, β-
catenin and β-actin. Whole cell lysates were prepared in
RIPA buffer supplemented with protease inhibitor cocktail.
Supernatant was collected by centrifugation at 13,000 rpm
for 25 min at 4 °C. Samples were then subjected to sodium
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE), transferred to nitrocellulose membranes and immu
noblotted. Protein bands were observed by Enhanced
Chemiluminescence detection (Amersham, Piscataway, NJ,
USA) of the specifically bound antibody. The quantitation
was done by densitometric analysis by “Quantity One”
software.
Xenograft experiments
Six-week old female Severe Combined Immunodeficient
(SCID) mice with tumors left untreated for 28 days were
randomized into two groups (ten animals in a group).
Group 1 was treated with 25 % polyethylene glycol (PEG)
alone. Group 2 was treated with PB in 25 % PEG at doses
of 1 mg/kg/day intraperitoneally. Tumors were measured
twice a week, and primary tumor volumes were calculated
using the formula V = 1/2a x b2, where ‘a’ is the longest
tumor axis, and ‘b’ is the shortest tumor axis.
Immunohistochemical analysis (IHC)
After 3 weeks of treatment, all OVCAR-5 tumor-bearing
mice were sacrificed by asphyxiation with CO2; tumors
were removed, measured, and prepared for IHC. Tumors
were removed and fixed in neutral buffered 10 % formalin
at room temperature for 24 h. Subsequently, the samples
were embedded in paraffin and sections were taken. Sec-
tions were deparaffinized and then subjected to Oct 4
(Cell Signaling Technology, Beverly, MA), Vimentin
(Clone V9, Chemicon International, Temcula, CA) and N-
cadherin (Clone 13A9, Santa Cruz Biotechnology, Santa
Cruz, CA) according to the manufacturer’s instructions
(DAB 150, (Millipore, Billerica, MA). The secondary anti-
mouse antibody was used before adding chromogen sub-
strate. Stable diaminobenzidine was used as a chromogen
substrate, and the sections were counterstained with a
hematoxylin solution. Photographs of the entire cross-
section were digitized using an Olympus camera (DP70).
Statistical analysis
The independent-sample paired two tailed student t-test
was used to test the probability of significant differences
between different experimental groups. FACS results were
expressed as mean ± S.D from at least three independent
experiments. Statistical significance was defined as (*)
p ≤ 0.05 and (**) p ≤ 0.005. Error bars were given on the
basis of calculated S.D values. All experiments were
repeated at least thrice.
Results
Intrinsic tumor subtype and BRCA1 status can determine
the percentage of the BCSCs within cancer cells
A comparison of the variations in the percentages of SP,
CD44+/24–/low and ALDH1+ cells among breast cancer
cell lines of different origins with varied receptor status
has not been reported. Hence, we studied the effects of
varied receptor status and possible effects of BRCA1
gene expression on these subcellular populations. The
cells showing low staining at both 635 nm and 488 nm
were identified as the Hoechst excluding side population
(SP) cells. Hoechst excluding SP cells constituted less
than 2 % of the total breast cancer cell population in
four out of the five cell lines analyzed. The percentage of
SP in HCC1937 (2.7 ± 0.42 %) was about 1.5 times
higher than that in HCC1937/wt BRCA1 cells (1.85 ±
0.21 %) (p < 0.05) (Fig. 1a). The putative BCSCs were also
identified in all the five cell lines and isolated based on the
CD44+/24–/low marker profile as described previously [6,
14]. Studies have suggested that the percentage of CD44
+/24–/low putative CSCs present would vary between can-
cer cell lines and this percentage is determined by two
main factors: the origin of the cell line and the receptor
status [9]. Among the normal-like tumor forming cell
lines, the BRCA1-mutated MDA-MB-436 harbored more
CD44+/24–/low cells (95 ± 1.4 %) than MDA-MB-231
(90.67 ± 1.75 %) (Fig. 1b). Similarly, in basal-like tumor
forming cell lines, the CD44+/24–/low cells were enriched
in BRCA1-defective HCC1937 (52.7 ± 1.84 %) when
compared to HCC1937/wt BRCA1 (30.6 ± 5.0 %) that
possesses a wild type BRCA1. Thus, the CD44+/24–/low
expression profile paralleled a BRCA1 defect though the
general predominance exhibited tumor sub-type specifi-
city with normal-like tumor forming cells (MDA-MB-436
and MDA-MB-231) possessing more CD44+/24–/low cells
than the basal-like tumor inducing cell lines (HCC1937
and HCC1937/wt BRCA1).
A tumor sub-type independent increase in numbers of
ALDH1+ cells was observed in BRCA1-mutated cell lines
MDA-MB-436 (8.4 ± 0.2 %) and HCC1937 (6.9 ± 0.5 %)
when compared to cells possessing a wild type BRCA1
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(Fig. 1c). ALDH1+ cells from HCC1937 showed maximum
sphere forming capability followed by MCF7. MDA-MB-
231 and MDA-MB-436 formed comparable number of
spheres after 7 days in culture while HCC1937/wt BRCA1
cells showed the least capability for in vitro mammosphere
formation (Fig. 1d). The ALDH1 negative (ALDH1-) cells
from HCC1937 and MDA-MB-436 were unable to form
spheres in culture when compared to ADH1- cells isolated
from MCF7, MDA-MB-231 and HCC1937/wt BRCA1 cell
lines which formed a few spheres in non-adherent culture
(. 1E). Hence, ALDH1, as a BCSC marker showed a spe-
cific association with BRCA1-defective breast cancers and
BRCA1 has a cardinal effect on BCSC numbers and
properties.
The inclusion of five cell lines with largely varied geno-
types made it difficult to draw corroborating conclusions
from confirmatory experiments. The two isogenic cell
lines HCC1937 and HCC1937/wt BRCA1 that differed
exclusively in the expression and functionality of BRCA1,
showed significant differences in sphere forming capability
(p < 0.005), a hallmark of CSCs. Hence, rest of the study is
centered on these two TNBC cell lines.
BRCA1 can influence the EMT traits and proliferative
potential of BCSCs
To further assess how BRCA1 influences cancer stem-
ness, we compared and contrasted between the EMT
and stem cell marker expression patterns in HCC1937
and HCC1937/wt BRCA1. HCC1937/wt BRCA1 cells
showed the presence of a distinct CD44high/24–population
(3.07 ± 1.12 %) within its CD44+/24–/low (30.6 ± 5.0 %) puta-
tive cancer stem cell population (Fig. 2a, Additional file 1:
Figure S1). This population was not observed in HCC1937
cells (Fig. 2b). Studies have attributed the presence of such
a population to a more mesenchymal phenotype that paral-
lels EMT traits in cell lines [29, 30]. A comparison of the
expression of the EMT markers [Snail, Slug, Vimentin, α-
SMA (mesenchymal marker)] and the stem cell markers
(Oct 4 and β-catenin) indicated that mammospheres of
HCC1937/wt BRCA1 exhibited a higher expression of the
EMT markers while HCC1937 showed a higher expression
of the stem cell markers (Fig. 2c). HCC1937 mammo-
spheres displayed a membrane localization of β-catenin
indicative of retention on cell membrane possibly prior to
nuclear localization following activation of Wnt signaling,
while HCC1937/wt BRCA1 mammospheres showed slight
membrane as well as diffuse cytosolic expression. The
cytoplasmic expression of β-catenin is indicative of the
absence of Wnt signaling and hence induction of proteoso-
mal degradation of the protein [31]. Additionally, β-catenin
expression levels were also much higher in mammospheres
of HCC1937 than HCC1937/wt BRCA1, while parental,
adherent cells exhibited an opposite trend (Fig. 2c). These
observations were corroborated by the microarray analysis
of HCC1937 and HCC1937/wt BRCA1 mammospheres
(Additional file 2: Table S1).
Plumbagin shows selective sensitivity for BRCA1 defective
breast cancer cells
We now went on to study if PB that has been shown to
the selective to BRCA1-defective ovarian cancer cells [23]
could also selectively target BRCA1-defective basal-like
breast cancer cells. Immunofluorescence and western
blotting were used to analyze the expression and intracel-
lular localization of BRCA1 in HCC1937 and HCC1937/
wt BRCA1 cell lines. We confirmed the low, cytosolic
expression of BRCA1 in HCC1937 while in HCC1937/wt
BRCA1, the BRCA1 protein was expressed and localized
specifically to the nucleus (Additional file 3: Figure S2).
This was expected as the truncated, non-functional
BRCA1 expressed by HCC1937 has been observed in
nucleus as well as the cytoplasm [32]. Cell proliferation
assay revealed that PB is highly selective towards the
HCC1937 cells with 5 μM concentration inhibiting prolifer-
ation in 56 % cells while in HCC1937/wt BRCA1 only 25 %
inhibition of proliferation was observed (Fig. 3a, Additional
file 2: Table S2). CP exhibited moderate selectivity towards
BRCA1-defective cells as well, with 200 μM concentration
causing 54 % growth inhibition in HCC1937/wt BRCA1
and 62 % inhibition in HCC1937 cells (Fig. 3b).
siRNA knockdown of BRCA1 showed that the HCC1937
cell line which possesses a C-terminus mutated BRCA1 did
not show any difference in susceptibility to PB as assessed
by MTTassay, while there was a prominent decrease in cell
proliferation in the HCC1937/wt BRCA1 cells upon block-
ing BRCA1 (Additional file 4: Figure. S3). Thus, the activity
of PB is closely linked to the BRCT domain 2 of BRCA1
that is absent in HCC1937 cell line.
Plumbagin can target BCSCs
To assess whether the ALDH+ ‘putative CSCs’ could be
specifically targeted based on the presence or absence of
functional BRCA1 protein, we analyzed the effects of PB
on these populations of cells. In vitro studies with regard
(See figure on previous page.)
Fig. 1 ALDH1+ cells and not ALDH1- cells from BRCA1-defective breast cancer cell lines can form spheres. Graph showing the percentages of SP
(a), CD44+/24–/low (b) and ALDH1+ (c) cells among the various breast cancer cell lines employed in this study. By all these three methods of identification,
the CSC population was significantly higher in BRCA1-defective HCC1937 when compared to HCC1937/wt BRCA1. d and (e) A comparison of the in vitro
sphere forming ability of ALDH1+ and ALDH1- cells from various cell lines indicating the inability of ALDH1- cells from BRCA1-defective cell lines to form
spheres thus supporting that the ALDH1+ population from these cell lines entirely represents the BCSCs. Scale = 100 μm
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to the BRCA1-defective scenario showed that the number
of ALDH1+ cells as well as mammosphere forming effi-
ciency significantly reduced in a dose dependent manner
after treatment with < IC50/2 (1.0 μM) and < IC50/4 (0.5 μM)
concentrations of PB. HCC1937 cells showed a significant
dose dependent reduction in sphere forming efficiency
upon PB treatment when compared to HCC1937/wt
BRCA1 cells at 0.5 μM (p = 0.0001) and 1.0 μM (p = 0.01)
concentrations (Fig. 3c and d). However, when the direct
effect of PB on BCSC numbers was analyzed, HCC1937/wt
Fig. 2 BRCA1 determines the frequency of stem cells or EMT marker expressing cells within cell lines. a The distinct CD44high/24–population (represented
by the black arrow) possessing mesenchymal properties is observed within the CD44+/24–/low cells (P4) in HCC1937/wt BRCA1. b Such a population is
not discernable within the HCC1937 cell line. c Marker profiling of mammospheres shows better expression of EMT markers (Snail, Slug, Vimentin) and
mesenchymal marker (α-SMA) by HCC1937/wt BRCA1 cells. Expression of stem cell markers (Nuclear Oct 4 and membrane bound β-catenin) was more
prominent in the HCC1937 cell line as observed by immunofluorescence as well as western blotting. Scale = 50 μm. “Ah” and “Mm” in western blot
represents Adherent and Mammospheres respectively
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Fig. 3 (See legend on next page.)
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BRCA1 cells showed a surprising enrichment of the
ALDH1+ cellular compartment upon PB treatment from
3.2 % in control cells to 8.1 % in 0.5 μM and 11.3 % in
1.0 μM concentrations of PB (Fig. 3e). A dose dependent
reduction in sphere formation efficiency and ALDH1+ cell
numbers was indicative of the ability of PB to specifically
target BRCA1-defective BCSCs. A direct inhibition of
sphere formation selectively in HCC1937 in 3D culture
was observed when compared to HCC1937/wt BRCA1
which showed a slight, progressive increase in size of
spheres from day 5 to day 15 (Fig. 4a).
Interstingly, the graph of Aldefluor assay in Fig. 3e shows
that the HCC1937/wt BRCA1 CSCs are enriched by PB
treatment. This observed increase in the ALDH1+ cells
within the HCC1937/wt BRCA1 cell line post PB treat-
ment, could not be correlated directly to ABCG2 expres-
sion as has been reported earlier [33] since HCC1937
expressed higher levels of ABCG2 than HCC1937/wt
BRCA1 (Fig. 4b). Immunofluorescence analysis of PB
treated mammospheres showed prominent membrane
localization and marginally increased expression of ABCG2
in HCC1937/wt BRCA1 cell line. However, no such change
was observed in the HCC1937 derived spheroids formed in
presence of PB (Fig. 4c). Hence, the increase in ALDH1+
cells in HCC1937/wt BRCA1 cells could be attributed to
the more robust membrane localization rather than in-
creased expression of the drug efflux pump ABCG2 in
comparison to HCC1937.
PB was found to induce reactive oxygen species (ROS)
selectively in HCC1937 mammospheres while the ROS
levels of HCC1937/wt BRCA1 spheres remained unaffected
as evidenced by DCF-DA staining (Fig. 4d) indicating that
the oxidative stress created was effectively taken care of and
hence may not be cytotoxic to HCC1937/wt BRCA1 mam-
mospheres. We also find that DNA DSBs are more in
HCC1937 than in HCC1937/wt BRCA1 when treated with
PB as DNA DSBs could not be repaired probably because
of the absence of functionally active BRCA1 (Additional file
5: Figure S4).
A comparison of PB with the standard drug CP was also
performed. The concentrations of CP used were ≤ IC50/2
(100 μM) and ≤ IC50/4 (50 μM). When HCC1937 and
HCC1937/ wt BRCA1 cells were treated for 48 h and
Aldefluor assay performed, there was a dramatic increase
in the number of ALDH1+ cells to 27.3 % in the 50 μM
treatment and 28.5 % in the 100 μM CP treatment (Fig. 4e)
from 4.0 ± 0.9 % in untreated control HCC1937/wt BRCA1
cells. An enrichment of ALDH1+ cellular sub-population
to 11.0 % was observed in HCC1937 cells treated with
100 μM CP for 48 h (Fig. 4e) from 5.4 ± 0.4 % in untreated
condition.
Plumbagin can target CSCs in ovarian cancer bearing SCID
mice
To assess if the CSC targeting effects of PB could be ex-
tended to ovarian cancers as well, we performed immuno-
histochemical analysis on ovarian cancer xenografts to
study the expression of different EMT/stem cell markers.
Earlier studies from our group as well as other groups
have found PB to be effective in targeting ovarian cancer
cells [24]. However, plumbagin to a lesser extent targets
the BRCA1- competent cells as well. To investigate this
further in ovarian CSCs, OVCAR-5 xenografts in NOD/
SCID mice were subjected to immunohistochemical ana-
lysis with antibodies for Oct 4, N-cadherin and Vimentin
and it was found that PB treatment reduced the expres-
sion of all the three markers with the most prominent
being the reduction in N-cadherin mesenchymal marker
expression (Fig. 5) followed by Vimentin and Oct 4 ex-
pression. Hence, PB can putatively target ovarian CSCs by
predominantly affecting the N-cadherin expressing cells
and to a lesser extent by targeting the mesenchymal cells
that express Vimentin and stem cells that express Oct 4.
The studies on OVCAR5 xenografts provide prelimin-
ary evidence for the possibility of targeting CSCs with
plumbagin.
Discussion
Goodell et al., 1996, showed that the low Hoechst staining
population could be identified as a special, drug effluxing
‘Side Population’ (SP) that conferred drug resistance to can-
cer cells and was responsible for relapse [34]. Subsequently,
side population cells from various cancers were isolated
using the property of exclusion of the Hoechst 33,342 dye
and all these isolated populations showed long-term prolif-
erative potential and the ability to differentiate into the
mesenchymal cell lineage [35, 36]. The possible roles played
by the drug efflux pumps in CSCs have also been elucidated
with the drug resistance protein ABCB1 recently being
implicated in the functioning of Renal Cell carcinoma
SP cells [37]. Our results suggest the existence of SP
cells with 1–2.7 % predominance across breast cancer
(See figure on previous page.)
Fig. 3 Cytotoxicity of PB is selective to BCSCs from BRCA1-defective breast cancer cell line. Effects of (a) Plumbagin and (b) Carboplatin on the
proliferation of HCC1937 and HCC1937/wt BRCA1 cells. c PB reduces the sphere forming efficiency in terms of size and (d) number of spheres formed
in a dose dependent manner in HCC1937 cells when compared to HCC1937/wt BRCA1 cells. Scale = 100 μm. e Reduction in the ALDH1+ population
after PB treatment observed in HCC1937 cells while an enrichment of ALDH1+ stem cells upon PB treatment was observed in HCC1937/wt BRCA1 cells
by flow cytometry and graph showing the variation in the percentages of ALDH1+ populations harbored by the breast cancer cell lines after treatment
with≤ IC50/2 (1 μM ) and≤ IC50/4 (0.5 μM) concentrations of PB
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Fig. 4 (See legend on next page.)
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(See figure on previous page.)
Fig. 4 BRCA1-defect specific effects of PB are attributable to production of ROS and weak membrane localization of ABCG2. a 15-day Matrigel culture of
mammospheres derived from HCC1937 cells and HCC1937/wt BRCA1 cells shows the selective inhibition of sphere formation in HCC1937 in the presence
of 0.5 μM PB. b the ABCG2 expression in these cell lines. c ABCG2 expression in HCC1937 and HCC1937/wt BRCA1 derived mammospheres formed in
presence of varying concentrations of PB shows improved membrane localization of ABCG2 after PB treatment in HCC1937/wt BRCA1 mammospheres.
Cells were treated with PB on day 1, mammospheres were supplemented with growth media without PB on day 4 and mammospheres were analyzed
on day 7 (d) Variation in the production of ROS in PB treated spheres of HCC1937 and HCC1937/ wt BRCA1 cell lines observable as a bright green
fluorescence by DCF-DA staining. e Aldefluor assay after 48 h treatment of HCC1937 and HCC1937/wt BRCA1 cells with sub-cytotoxic concentrations of CP
shows a dose dependent enrichment of ALDH1+ cells in both the cell lines. Scale = 100 μm
Fig. 5 PB reduces expression of ‘stemness’ amd EMT markers in ovarian cancer xenografts. Immunohistochemical analysis of the expression of Oct 4,
N-cadherin and Vimentin in OVCAR-5 xenografts before and after PB treatment. A prominent reduction in N Cad, Vimentin and Oct 4 expressing cells was
observed in PB treated samples. Scale = 200 μm
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cell lines from varying subtypes. MDA-MB-436 (1.2 ±
0.1 %) and HCC1937 (2.7 ± 0.4 %), both BRCA1-defective
cell lines showed large variation in the SP abundance. No
direct correlation could be drawn between BRCA1 status
and SP levels as other factors governing the genotype of
the cells may be important determinants. Hence, SP ana-
lysis may not be the method for identification of BRCA1-
defective BCSCs across subtypes. However, a reduction in
the SP cell numbers was observed when BRCA1 was in-
troduced into HCC1937.
It was found that very small cell numbers of the CD44
+/24–phenotype were capable of initiating mouse mammary
tumors [6, 14]. The CD44+/24–/low cell population also
showed the properties of self renewal and multi-lineage
differentiation as well and thus, this phenotype of CD44
+/24–was tagged as the putative breast cancer stem cell
phenotype. Studies have suggested that the percentage of
CD44+/24–/low putative CSCs present would vary between
cancer cell lines and this percentage is determined by two
main factors: the origin of the cell line and the receptor
status [9]. When isolated from cancer tissues, the stem cell
abundance is dependent on many more biological markers
such as tumor size, histological grade, lymph node lesions,
receptor status and molecular subtype of the tumor [33, 38,
39]. A comparison of the sub-cellular percentages of these
populations in five different cell lines brought to light the
fact that the molecular subtype of the tumor induced by
the cell lines and the BRCA1 status were important in
determining the CD44+/24–/low and the ALDH1+ cell
population numbers respectively. This is in addition to the
already known determinant namely, the cell type of origin
[9]. It was observed that the BRCA1- mutated cell lines
were enriched for ALDH1+ cells in both normal-like tumor
forming (MDA-MB-436) and basal-like tumor forming
(HCC1937) cell lines. ALDH1 positivity was thus associated
with a BRCA1 defect as reported earlier [20] and we add-
itionally find this association to be independent of tumor
sub-type unlike the CD44/24 profile. A similar link was also
observed between the CD44+/24–/low profile and BRCA1
expression status in basal–like breast cancer cells, as
HCC1937 expressed higher CD44+/24–/low cells than the
HCC1937/wt BRCA1 cell line. Estrogen Receptor and Pro-
gesterone Receptor positive MCF7 cell line exhibited the
least number of SP, CD44+/24–/low and ALDH1+ cells. This
could be due to its low invasive capabilities in comparison
to the TNBC cell lines [40]. The aggressive TNBCs of
basal origin showed a high expression of CD44+/24–/low
cells with MDA-MB-231 and MDA-MB-436 that formed
normal like breast cancers exhibiting higher levels of these
putative BCSCs. The existence of 80-90 % CD44+/24–/low
cells in MDA-MB-231 and MDA-MB-436 adds credence
to earlier reports that this population is not exclusively
constituted of BCSCs [41]. Further, the number of CD44
+/24–/low cells was significantly lower in HCC1937 when
compared to MDA-MB-436 (p = 0.0001) though both
were BRCA1-mutated. Thus, the CD44+/24–/low popula-
tion abundance could be independent of BRCA1 expres-
sion and dependent on the tumor sub-type.
The use of the three established methods for isolation of
CSCs followed by in vitro self renewal analysis by mam-
mosphere formation studies have thus brought out the
ALDH1+ phenotype as the best candidate putative stem
cell marker for BRCA1-defective breast cancer cells. This
is because the ALDH1+ cells from BRCA1-defective cell
lines formed large mammospheres in comparison to
ALDH1+ cells from BRCA1-competent breast cancer
cells. Also, the ALDH1- cells from HCC1937 and MDA-
MB-436 cells failed to form spheroids in culture. The
ALDH1- cells from MCF7 and HCC1937/ wt BRCA1
possessing a wild type BRCA1 gene formed spheroids
though fewer and smaller in size than those formed by the
corresponding ALDH1+ cells.
A recent report indicates ALDH1 positivity to be a better
marker for relapse than the CD44+/24–/low profile [42].
Also, the CD44+/24–/low profile has been found to repre-
sent the slow cycling, mesenchymal BCSCs while the
ALDH1+ cells are the rapidly proliferating epithelial
BCSCs [43]. This being the case, we decided to analyze the
HCC1937/wt BRCA1 and HCC1937 cells for their mesen-
chymal and proliferative characteristics. Immunofluores-
cence based profiling of the spheroids generated from the
two cell lines indeed showed a more robust expression of
the EMT markers Snail, Slug and Vimentin and mesenchy-
mal marker α-SMA in the HCC1937/wt BRCA1 mammo-
spheres and a higher expression of the stem cell markers
Oct 4 and β-catenin in the HCC1937 cell line. Concor-
dantly, we also observed for the first time the existence of
a CD44high/24–population within the HCC1937/wt BRCA1
cell line which is absent in HCC1937 cells, possibly respon-
sible for the prominent mesenchymal nature of HCC1937/
wt BRCA1 cells that showed the least in vitro sphere form-
ing ability while the HCC1937 harboring proliferating stem
cells formed the maximum number of spheres in culture
as shown in Fig. 1d.
Earlier reports from our group have established the
ability of PB, a naturally occurring naphthoquinone to
induce cytotoxicity specifically and selectively in BRCA1
defective ovarian cancers [21–24, 44]. The C-terminal end
of the BRCA1 protein has been shown to be involved in
phospho-protein binding thus playing a direct, central role
in the functioning of the protein [45, 46]. HCC1937 has a
5382insC mutation that leads to the synthesis of a C-
terminal truncated BRCA1 protein [47, 48]. The silencing
of BRCA1 and associated difference in susceptibility of
HCC1937/wt BRCA1 to PB show that a mutated BRCT
domain 2 at the C-terminus of BRCA1 plays an important
role in mediating the specific activity of PB in BRCA1-
defective cancers. Hence, we suggest that the activity of PB
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is closely linked to the presence of a functional BRCT
domain 2 of BRCA1.
A number of varied targets of plumbagin have been iden-
tified over the years [26] that effected cell viability by the
induction of G2-M arrest, autophagy, apoptosis as well as
inactivation of NK-kB and Bcl2 [27, 49]. However, the
possible effects of PB in CSCs are still unexplored and have
been analyzed in this study. An agent that has a putative
ability to target CSCs exhibits a three-pronged effect in
vitro by inducing a reduction in number and size of mam-
mospheres as well as directly reducing or abrogating the
CSC marker expressing population. Such a decrease in
ALDH1+ cells associated with Wnt signaling was observed
by Y Li et al., 2010 with sulphorafane treatment in breast
cancer cells [50]. In vitro experiments to study the effects
of PB on BCSCs gave promising activity where as the
standard drug carboplatin caused an increase in the
ALDH1+ stem cell numbers post treatment. This observed
increase after treatment is concordant with carboplatin
being an effective anti-cancer drug capable of killing and
clearing off the bulk tumor cells rapidly. This consequently
triggers the otherwise quiescent stem cells (ALDH1+ cells)
to enter the cell cycle, thus leading to a dramatic increase
in the number of ALDH1+ ‘stem cells’ and possibly ac-
counting for the few incidences of relapse after chemo-
therapy with carboplatin. This enrichment of ALDH1+
BCSCs in PB treated HCC1937/wt BRCA1 could be
explained as a direct effect of membrane localization ra-
ther than increased expression of the drug efflux pump
ABCG2 (Fig. 4e). However, in HCC1937, PB shows the
promising ability to directly reduce the number of ALDH1
+ BCSCs possibly by inhibiting the membrane localization
of ABCG2, as well as by triggering ROS generation [51,
52]. The ROS signaling induced by PB could be through
the activation of PI5K-1B protein that then induces ROS
production and/ or triggers loss of mitochondrial mem-
brane potential, and apoptosis [23, 53]. This further cor-
roborates the specificity of PB to target BRCA1-defective
cells and also provides a reason for the BCSC enrichment
observed in PB treated HCC1937/wt BRCA1 spheres in
which the ROS induction by PB is seen to be effectively
nullified and hypoxic condition is maintained. Hypoxia is a
well-documented inducer of EMT as well as CSC pheno-
types [54–56]. We have shown earlier that HMOX1 is
about 6.6 fold high in BRCA1 deficient than BRCA1 profi-
cient condition when treated with plumbagin [44]. The
sustained high levels of ROS and corresponding high levels
of HMOX1, compared to moderate-low levels of ROS and
HMOX1 observed in BRCA1 wild type condition, could
induce apoptosis in BRCA1-deficient condition instead of
survival. Thus, PB which is reported earlier to have a spe-
cific cytotoxicity in BRCA1-defective ovarian cancers, is
found in this study to possess the ability to target BRCA1-
defective BCSCs as well (Fig. 6). Recent studies have found
the involvement of the Wnt/β-catenin-ABCG2 signaling
pathway in chemoresistance and tumor-initiating capacity
of ovarian cancer cells [57]. However, none of these have
studied the differences in sub-cellular localization of
ABCG2.
Immunohistochemical analysis of ovarian cancer xeno-
grafts has provided preliminary in vivo evidence for the
ability of PB to target CSCs. A reduction in Vimentin
(EMT marker), N-cadherin (Mesenchymal marker) as well
as Oct 4 (Stem cell marker) expressing cells after PB treat-
ment shows for the first time, the ability of the naphthoqui-
none to target CSCs in vivo. Studies from our group have
earlier shown that Plumbagin can target BRCA1-defective
breast (unpublished data) as well as ovarian cancers [21]
more effectively than it can target BRCA1-competent cells
from both cancers. The studies on OVCAR5 xenografts
provide preliminary evidence for the possibility of targeting
BCSCs with plumbagin. This could be accomplished with
greater selectivity to BRCA1-defective BCSCs if the in vitro
effects of PB are reflected in vivo too. This paves way for
further xenograft experiments with BRCA1-defective breast
cancer cell lines which could bring out the specific and
pronounced effects of PB in BRCA1-defective BCSCs as is
expected from the in vitro and in vivo data generated from
this study.
This study shows a possible role for BRCA1 in deter-
mining the EMT and stem cell characteristics of BCSCs
and also links BRCA1 and the marker expression profile
of BCSCs to the existence of a CD44high/24–sub-popula-
tion. In support of this, suppression of EMT by BRCA1
and expression of Slug and Snail in response to repression
of BRCA1 expression has been reported earlier [58, 59].
It has been very well proved that low levels of ROS help
CSCs to survive and lead to adaptive changes for tumor
progression. Shi et al., 2012 demonstrated that, the ROS
generated by xenobiotics tip the redox balance and kill
cancer cells while not affecting normal cells [60]. In our
study, the ability of PB to induce DSBs (Additional file 5:
Figure S4) coupled with its ability to generate ROS in
HCC1937 mammospheres (Fig. 4d) leads to a ‘double effect’
where the increased ROS in the mammospheres stresses
the CSCs that are known to thrive in low ROS conditions
and the additional burden of DNA DSBs that cannot be
repaired due to a lack of functional BRCA1 causes the
CSCs to die. This is reflected in the reduction of ALDH1+
BCSC population after PB treatment. On the other hand,
PB is unable to induce ROS, DNA DSBs in HCC1937/wt
BRCA1 BCSCs which continue to thrive in the lower ROS
environments present in the PB treated mammospheres.
This leads to the increase in ALDH1+ BCSC numbers after
PB treatment. This is the maiden study addressing the abil-
ity of PB to target CSCs with selectivity for BCSCs from
BRCA1-defective breast cancer cell lines. At the molecular
level, ROS induced by PB in the BCSCs may be working
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partially through the Wnt/β catenin-ABCG2 pathway to
make BCSCs more susceptible to PB by preventing its
efflux [57, 61]. This aspect of the action of PB has to be
investigated further.
Thus, future studies aimed at targeted delivery of PB
into BRCA1-defective breast cancers could open up new
avenues for the complete abrogation of the cancer, includ-
ing CSCs, aiding relapse-free survival after chemotherapy.
Conclusion
In support of the recalcitrant nature of BRCA1-related
cancers to therapy, we show the predominant expression
of stem cell markers in mammospheres derived from
BRCA1-defective cancer cells in contrast to the EMT
markers expressed by BCSCs in a BRCA1-competent
condition. Majority of chemotherapeutics abrogate rapidly
proliferating bulk tumor cells, while quiescent, therapy
resistant CSCs are subsequently enriched. We demonstrate
for the first time that a naphthoquinone, PB selectively
reduces the ALDH1+ population in basal-like BRCA1-
defective breast cancer cells while enriching the ALDH1+
population in cancer cells harboring full length, functional
BRCA1, the reason for which has to be analyzed in future.
Carboplatin on the other hand, caused an enrichment of
ALDH1+ cells irrespective of BRCA1 status. PB also in-
duces ROS production- potentially culminating in cell
death- exclusively in the mammosphere-derived cells of
BRCA1-defective HCC1937. This study gives insights for an
effective treatment regimen that can inhibit CSC-induced
resistance to therapy and subsequent disease relapse.
Fig. 6 Model of BRCA1 defective BCSCs and response to anticancer agents. BRCA1 defective BCSCs are mostly positive for stem cell markers (Nuclear
Oct 4 and membrane bound β-catenin) while BRCA1 wild type BCSCs shows expression of EMT markers (Snail, Slug, Vimentin) and mesenchymal marker
(α-SMA). PB, an ROS inducer can cause DNA DSBs which cannot be effectively repaired in BRCA1 defective cells leading to apoptosis (unpublished data).
Also, very high levels of HMOX1 expression in BRCA1 deficient condition as reported earlier, may cause apoptosis induction. ROS mediated DNA damages
will be repaired and low levels of hypoxia created by PB can lead to low HMOX1 induction and further stem cell enrichment in BRCA1 wild type BCSCs. In
addition to this, drug efflux will not happen as ABCG2 membrane translocation is hampered in presence of PB in BRCA1 defective mammospheres. Due to
the presence of active ABCG2, drug efflux will also be high when treated with PB in BRCA1-wild type BCSCs. The same mechanism may be in action in
both the conditions after CP treatment
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Additional files
Additional file 1: Figure S1. Contour plot showing the distinct
CD44high/24- population (indicated by black arrow) in HCC1937/wt BRCA1
cell line in support of Fig. 2a. Here, the existence of the CD44high/24-/low cell
sub population possessing mesenchymal properties in HCC1937/wt BRCA1 is
more evident. (B) Expression and localization of BRCA1 in HCC1937 and
HCC1937/wt BRCA1 cell lines. (TIF 27522 kb)
Additional file 2: Table S1 and S2. Table S1. The fold change values
generated using the GeneSpring software after Microarray analysis of the
HCC1937 mammospheres in comparison to the HCC1937/wt BRCA1
mammospheres and are indicative of the genes whose expression is
directly or indirectly linked to BRCA1. Table S2. IC50 values of Plumbagin
(PB) and Carboplatin (CP). (DOCX 11 kb)
Additional file 3: Figure S2. Expression and localization of BRCA1 in
HCC1937 and HCC1937/wt BRCA1 cell lines by immunofluorescence and
western blotting. Quantitation of BRCA1 expression normalized with β-actin
in western blot by densitometry analysis is also indicated. (TIF 28769 kb)
Additional file 4: Figure S3. Cytotoxic effect (by MTT assay) of PB
(24 h treatment) in HCC1937 (A) and HCC1937/wt BRCA1 (B) after the siRNA
mediated blocking of BRCA1. HCC1937 and HCC1937/wt BRCA1 cells were
treated for 48 h with full length 2.4pM siRNA for BRCA1 (Eurogentec, Liège,
Belgium) (siRNA Sense (+dTdT), 19 bases in length, BRCA1 position 1857–1879,
GGUCAAGUGAUGAAUAUUA) as per manufacturer’s instructions followed by
treatment with PB for 24 h. (TIF 9107 kb)
Additional file 5: Figure S4. Comet Assay: DSB induced by PB (8 h
treatment) in HCC1937 (A) and HCC1937/wt BRCA1 (B) observed by comet
assay. HCC1937 and HCC1937/wtBRCA1 cells were treated for 8 h with varying
concentrations of PB (2.5uM, 5uM and 7uM) and comet assay performed after
neutral lysis of the treated cells. The top two panels show the HCC1937 and
HCCC1937/wt BRCA1 cells. Tails of damaged DNA are visible in HCC 1937 cells
after 5 uM and 7uM treatment with PB. The graph quantifies the Olive tail
moment indicating the extent of DNA damage. (TIF 2882 kb)
Additional file 6: Supplementary materials and methods. (DOCX 13 kb)
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